In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi.
暂无分享,去创建一个
[1] D. Loebenberg,et al. Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts , 2000, Antimicrobial Agents and Chemotherapy.
[2] Tropical disease research , 2000, Releve epidemiologique hebdomadaire.
[3] J. Ramirez,et al. Myocardial parasite persistence in chronic chagasic patients. , 1999, The American journal of tropical medicine and hygiene.
[4] J. Urbina. Chemotherapy of Chagas’ disease: the how and the why , 1999, Journal of Molecular Medicine.
[5] L. Kirchhoff. Chagas'Disease (American Trypanosomiasis): a Tropical Disease Now Emerging in the United States , 1999 .
[6] P. Wincker,et al. Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.
[7] P. Wincker,et al. Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870 , 1996, Science.
[8] O. Martins-Filho,et al. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease , 1995, Clinical and diagnostic laboratory immunology.
[9] L. Filardi,et al. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.